Visceral Leishmaniasis
42
2
4
29
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.9%
5 terminated out of 42 trials
85.3%
-1.2% vs benchmark
29%
12 trials in Phase 3/4
0%
0 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (42)
Human Bioequivalence Study of Liposomal Amphotericin B for Injection
Recurrent Visceral Leishmaniasis in HIV Co-Infection
Human Bioequivalence Study of Amphotericin B Liposome for Injection
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
Clinical Prognostic Score to Predict Relapse in VL
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
LAMP Assay for the Diagnosis of Visceral Leishmaniasis
Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Improved Case Detection and Vector Control for Visceral Leishmaniasis
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.
Asymptomatic Leishmania Infection in HIV Patients
A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
Immunogenetics of Visceral Leishmaniasis
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)